Perspective Therapeutics Inc. (CATX)vsEdwards Lifesciences Corp (EW)
CATX
Perspective Therapeutics Inc.
$0.84
+2.08%
HEALTHCARE · Cap: $131.27M
EW
Edwards Lifesciences Corp
$105.80
-0.01%
HEALTHCARE · Cap: $59.81B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 1631856% more annual revenue ($6.67B vs $409,000). EW leads profitability with a 15.3% profit margin vs 0.0%. EW earns a higher WallStSmart Score of 54/100 (C-).
CATX
Avoid29
out of 100
Grade: F
EW
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CATX.
Margin of Safety
+69.2%
Fair Value
$257.48
Current Price
$105.80
$151.68 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Strong operational efficiency at 30.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : CATX
The strongest argument for CATX centers on Price/Book, Debt/Equity.
Bull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 15.3% and operating margin at 30.1%. Revenue growth of 10.5% demonstrates continued momentum.
Bear Case : CATX
The primary concerns for CATX are EPS Growth, Market Cap, Profit Margin.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 60.5x leaves little room for execution misses.
Key Dynamics to Monitor
CATX profiles as a value stock while EW is a mature play — different risk/reward profiles.
CATX carries more volatility with a beta of 1.85 — expect wider price swings.
EW is growing revenue faster at 10.5% — sustainability is the question.
EW generates stronger free cash flow (507M), providing more financial flexibility.
Bottom Line
EW scores higher overall (54/100 vs 29/100), backed by strong 15.3% margins and 10.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Perspective Therapeutics Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Perspective Therapeutics Inc. (CATX) is a pioneering biotechnology firm focused on revolutionizing cancer care through the development of innovative radiopharmaceuticals. Leveraging state-of-the-art radioisotope technologies, CATX seeks to enhance the precision and effectiveness of cancer therapies, aiming to significantly improve patient survival rates across various malignancies. Backed by a seasoned leadership team and strong strategic alliances, the company is strategically positioned to drive advancements in targeted cancer treatments, addressing significant healthcare challenges in a competitive landscape.
Visit Website →Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?